



Cite this: *Med. Chem. Commun.*,  
2017, **8**, 780

## ***Nonomuraea* sp. ATCC 55076 harbours the largest actinomycete chromosome to date and the kistamicin biosynthetic gene cluster<sup>†‡</sup>**

Behnam Nazari,<sup>a</sup> Clarissa C. Forneris,<sup>a</sup> Marcus I. Gibson,<sup>a</sup> Kyuho Moon,<sup>a</sup> Kelsey R. Schramma<sup>a</sup> and Mohammad R. Seyedsayamdost<sup>\*ab</sup>

Glycopeptide antibiotics (GPAs) have served as potent clinical drugs and as an inspiration to chemists in various disciplines. Among known GPAs, complestatin, chloropeptin, and kistamicin are unique in that they contain an unusual indole–phenol crosslink. The mechanism of formation of this linkage is unknown, and to date, the biosynthetic gene cluster of only one GPA with an indole–phenol crosslink, that of complestatin, has been identified. Here, we report the genome sequence of the kistamicin producer *Nonomuraea* sp. ATCC 55076. We find that this strain harbours the largest actinobacterial chromosome to date, consisting of a single linear chromosome of ~13.1 Mbp. AntiSMASH analysis shows that ~32 biosynthetic gene clusters and ~10% of the genome are devoted to production of secondary metabolites, which include 1,6-dihydroxyphenazine and nomuricin, a new anthraquinone-type pentacyclic compound that we report herein. The kistamicin gene cluster (*kis*) was identified bioinformatically. A unique feature of *kis* is that it contains two cytochrome P450 enzymes, which likely catalyze three crosslinking reactions. These findings set the stage for examining the biosynthesis of kistamicin and its unusual indole–phenol crosslink in the future.

Received 16th November 2016,  
Accepted 23rd January 2017

DOI: 10.1039/c6md00637j

rsc.li/medchemcomm

### 1. Introduction

Glycopeptides antibiotics (GPAs) represent one of our most medicinally important and structurally beautiful cures.<sup>1–4</sup> Since the discovery of vancomycin (**1**, Fig. 1),<sup>5,6</sup> the founding member of this class, GPAs have served as indispensable weapons against Gram positive bacterial infections and recently as drugs-of-last resort against methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile*. The World Health Organization lists vancomycin as one of 200 essential medicines. The importance of GPAs in a clinical setting cannot be overstated.

The remarkable bioactivity of GPAs, which include teicoplanin (**2**),<sup>7</sup> another clinically deployed member of this class, is based on inhibition of cell wall biosynthesis by tight binding and sequestration of the D-Ala-D-Ala terminus of the growing muropeptide portion of the peptidoglycan.<sup>4,8,9</sup> This mode of action is made possible by the architecturally complex structure of GPAs, which contain a rigid, cup-shaped to-

pology that is locked in its structure *via* several biaryl and bisaryl ether crosslinks. Installation of these unusual modifications is of great biochemical interest and their mechanism of formation has yet to be fully elucidated.<sup>10,11</sup> Pioneering studies by Wohlleben, Süssmuth, and Robinson have shown that cytochrome P450 enzymes catalyze these transformations.<sup>12–17</sup> Specifically, the reaction of OxyB, which installs the first bisaryl ether crosslink in vancomycin, has been reconstituted *in vitro*.<sup>16,17</sup> However, only a few examples of these reactions have been demonstrated, and the enzymatic semi-synthesis of GPAs remains a long-standing and unaccomplished goal. The recent discovery of a so-called X-domain that recruits P450 enzymes during bisaryl ether bond formation in teicoplanin shows that GPAs still bear many surprises and lessons in biosynthesis.<sup>18–20</sup>

GPAs are categorized into five classes based on structural considerations.<sup>2</sup> Classes I–IV contain either biaryl or bisaryl ether crosslinks involving tyrosine, 4-hydroxyphenylglycine (Hpg), 3,5-dihydroxyphenylglycine (Dpg), or chlorinated derivatives of Tyr and Hpg. Class V GPAs are rare in that they incorporate tryptophan into the peptidic scaffold and contain characteristic indole–phenol crosslinks (Fig. 1). The only available biosynthetic gene cluster for a class V GPA is that of complestatin (**3**).<sup>21,22</sup> The P450 enzymes involved in side-chain crosslink formation in complestatin biosynthesis have yet to be characterized. While numerous class V GPA gene

<sup>a</sup> Department of Chemistry, Princeton University, Princeton, NJ 08544, USA.


E-mail: mrseyed@princeton.edu

<sup>b</sup> Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA

† The authors declare no competing interests.

‡ Electronic supplementary information (ESI) available. See DOI: 10.1039/c6md00637j





**Fig. 1** GPAs and secondary metabolites produced by *Nomonuraea* sp. ATCC 55076. Structures of vancomycin (1), teicoplanin (2), complestatin (3), and kistamicin (4) are shown. Gene clusters for geosmin (5), 2-methylisoborneol (6), and 1,6-dihydroxyphenazine (7) can be seen in the genome of ATCC 55076 and the latter was identified in culture supernatants. Clusters highly homologous to those of indigoidine (8) and coelichelin (9) are also contained in the genome of ATCC 55076. Nomuricin (10) was isolated from ATCC 55076 and structurally characterized. It is structurally similar to pradimicin Q (11). A gene cluster similar to that of xantholipin (12) is likely responsible for production of nomuricin.

clusters can be seen in the available bacterial genome database, they have not yet been linked to a cognate GPA. Conversely, kistamicin (4),<sup>23</sup> another prominent member of the class V GPAs, has not yet been linked to its biosynthetic genes.

In contrast to complestatin, kistamicin contains two bisaryl ether bonds and an indole-phenol crosslink (Fig. 1). To begin to understand the production of the class V GPAs as well as expand the genomic basis of these fascinating molecules, we herein report the complete genome sequence of *Nomonuraea* sp. ATCC 55076 (hereafter ATCC 55076), a kistamicin producer previously isolated from soil near the Kistna River in India. Aside from identifying and characterizing the kistamicin gene cluster (*kis*) *in silico*, we find that ATCC 55076 harbours the largest actinobacterial genome to date, with a single linear chromosome consisting of ~13.1 Mbp. In addition to *kis*, ATCC 55076 contains more than 30 secondary metabolite biosynthetic gene clusters that bear little homology to known ones, suggesting that this strain will

serve as an attractive target for future genome mining strategies in the search for new and useful small molecules.

## 2. Results and discussion

### 2.1 Kistamicin production by *Nomonuraea* sp. ATCC 55076

Kistamicin was originally isolated from *Microtetraspora pervosata* in the 1980s.<sup>23</sup> Like its relative complestatin, it exhibited potent antiviral activity as well as mild antibiosis against Gram positive bacteria. The producing strain was reclassified as a member of the *Actinomadura* genus, then a member of the rare actinomycete, *Nomonuraea*. We obtained *Nomonuraea* sp. ATCC 55076 and examined its ability to produce kistamicin using HPLC-MS. Production of kistamicin was not observed in the typical ISP2 actinomycete growth medium. We thus conducted an OSMAC-type approach,<sup>24</sup> in which we monitored kistamicin production in culture supernatants and mycelial extracts in six distinct media. Kistamicin was observed under only one condition, a fish

meal-based medium, which we designed according to the original reports.<sup>23</sup> Acetone extraction of the mycelial pellet yielded nearly pure kistamicin (Fig. 2), thus obviating the extensive purification protocol originally employed by Naruse *et al.*<sup>23</sup> Consistent with previous reports, ATCC 55076 proved to be a prolific producer when cultured in the appropriate medium delivering kistamicin yields of  $>3$  mg L<sup>-1</sup> culture. The identity of kistamicin was verified by high-resolution MS (HR-MS,  $[M + H]_{\text{calc}}^{+}$  1171.3241,  $[M + H]_{\text{obs}}^{+}$  1171.3256) as well as by comparison with reported 1D/2D NMR data (Fig. S1, S2 and Table S1†). That kistamicin is biosynthesized only in certain culture media suggests that an as-of-yet unknown trace element, component, or culture condition is required for its production.

## 2.2 Whole genome sequencing of *Nonomuraea* sp. ATCC 55076

To find the biosynthetic gene cluster of kistamicin, we used next-generation genome sequencing and bioinformatic methods. Genomic DNA was isolated and its sequence determined using the PacBio single molecule real-time (SMRT) sequencing technology.<sup>25</sup> A long insert library of  $\sim 8$  kb was prepared and sequences generated from 3 SMRT cells. A total of  $\sim 227\,000$  reads from an average fragment size of 7.8 kb were used to construct the genome sequence. The hierarchical genome assembly process (HGAP)<sup>26</sup> allowed *de novo* assembly of the entire chromosome resulting in a single contig of  $\sim 13.1$  Mbp with 130-fold coverage and an average GC content of 72.1%, consistent with the reported GC content for this genus (Fig. 3).<sup>27</sup> This marks the first complete genome sequence for a member of the genus *Nonomuraea*. The largest actinobacterial genome to date is that of *Streptomyces bingchengensis* at 11.9 Mbp and 10 023 open reading frames (ORFs).<sup>28</sup> In a phylum known for its large genomes, the single, 13.1 Mbp linear chromosome of *Nonomuraea* sp. ATCC


55076 is the largest of any sequenced actinobacterium to date. The genome sequence has been deposited at GenBank (BioProject ID PRJNA348567, accession CP017717) and IMG (ID 98346).

Genome annotation using RAST<sup>29</sup> predicted a record  $>11600$  coding sequences, about 50% each on the leading and lagging strands. Among these, we found a staggering 96 predicted sigma factors, 187 two-component signalling systems and 536 transcriptional regulators (Fig. 3). Consistent with the saprophytic nature of ATCC 55076, we also detected over  $\sim 400$  secreted proteins and enzymes, as well as  $\sim 1100$  proteins with a predicted transport function. The large numbers of predicted regulatory proteins, transporters, sigma factors, and secondary metabolite biosynthetic genes (see below), in part, explain the large genome size of ATCC 55076.

## 2.3 Secondary metabolome analysis


To assess the potential of ATCC 55076 for secondary metabolite synthesis, antiSMASH<sup>30</sup> analysis was carried out, revealing  $\sim 32$  biosynthetic gene clusters, with an average length of 38 kb (Table 1). Thus, this strain devotes a remarkable  $\sim 9.6\%$  of its genome to secondary metabolite production compared to 4.5% and 6% for the representative actinomycetes *Streptomyces coelicolor* or *Streptomyces avermitilis*, respectively, both of which have significantly smaller chromosomes (approx. 8.5 Mbp).<sup>31</sup> The genome of ATCC 55076 is especially rich in biosynthetic gene clusters for terpenes (6 total) and bacteriocins (8 total), including lantipeptides and lasso peptides. Only three of the 32 clusters can be confidently assigned to a known secondary metabolite, that of geosmin (5) and 2-methylisoborneol (6) – both of which show complete similarity to previously characterized gene clusters<sup>30,32</sup> – as well as kistamicin, which bears high sequence similarity to the cluster of A40926, a teicoplanin-type GPA (Table 1). Biosynthetic gene clusters for indigoidine (8) and coelichelin (9) also share high similarities (80% and 63%, respectively) with previously characterized relatives.<sup>33,34</sup> However, these molecules were not detected in cultures of ATCC 55076.

In an effort to assign additional molecules, we carried out an MS/MS network analysis of the secreted metabolome of ATCC 55076. This led to identification of 1,6-dihydroxyphenazine, a bioactive molecule that has previously been isolated from bacteria (7, Fig. 1, S3 and Table S2†).<sup>35</sup> A gene cluster coding for a phenazine-like molecule can also be spotted in the genome of ATCC 55076 and is likely responsible for production of 7 (see Table 1, cluster 25). An aromatic secondary metabolite, identified by its UV-vis spectrum, was also produced at appreciable levels in ATCC 55076 cultures. Comparison of its high-resolution mass ( $[M + H]_{\text{obs}}^{+} = 463.1020$ ) to a library of known natural products showed that it was a new compound; we have given it the trivial name nomuricin. It was purified to homogeneity and analyzed by UV-vis spectroscopy and 1D/2D NMR. Nomuricin's key UV-vis feature, a broad absorption peak at  $\sim 460$  nm, is consistent with a



**Fig. 2** Isolation of kistamicin via mycelial extraction. HPLC-MS analysis of the acetone extract of the ATCC 55076 mycelium, prepared in a fish meal-based medium. Under these conditions, nearly pure kistamicin is obtained at high titres. The peak at Rt  $\sim 10$  min corresponds to kistamicin. Inset, UV-vis spectrum of kistamicin.





**Fig. 3** Genome map of the linear chromosome of *Nomonuraea* sp. ATCC 55076. Starting from the outside, the rings display the genome position in kb starting with *dnaA* (ring 1), predicted ORFs on the leading strand (ring 2), deviation from average GC content of 72.1% (ring 3), predicted ORFs on the lagging strand (ring 4), location of sigma factors (96 total, ring 5), position of two-component signalling systems (187 total, ring 6), position of transcriptional regulators (536 total, ring 7), GC skew (ring 8), and position of secondary metabolite biosynthetic gene clusters (innermost ring 9).

hydroxylated anthraquinone skeleton, as revealed by comparisons with di-hydroxy-anthraquinone and other hydroxy-anthraquinone-containing natural products (Fig. S4 and Table S3<sup>‡</sup>). Further analysis by 1D/2D NMR revealed that nomuricin contains a benz[a]anthracycline scaffold with a benzoic acid moiety and an unusual hydroxymethyl substituent (10, Fig. 1, Fig. S4–S6 and Table S3 and S4<sup>‡</sup>). This scaffold is shared with the pradimicin aglycone (11), which has been isolated from *Actinomadura hibiscus* (Fig. S6<sup>‡</sup>),<sup>36,37</sup> a relative of ATCC 55076. Mosher ester analysis revealed the *R* stereoconfiguration for the chiral carbon bearing the hydroxyl group (Fig. 1 and S7<sup>‡</sup>), and thus completed the structural assignment of nomuricin.

Anthracycline scaffolds are typically biosynthesized by type II polyketide synthases (PKS). The genome of ATCC 55076 contains only one such gene cluster, which shares significant homology with the xantholipin biosynthetic genes (12, Fig. 1, Table 1).<sup>38</sup> We suspect that this type II PKS cluster is responsible for nomuricin biosynthesis, though additional studies are necessary to test this hypothesis. Nomuricin did not exhibit growth-inhibitory activity when tested against *S. aureus*, *Bacillus subtilis*, *Escherichia coli*, *Pseudomonas aeruginosa* or *Saccharomyces cerevisiae* at concentrations up to 50  $\mu$ g mL<sup>-1</sup>. Broader screens are necessary to characterize the biological activity of nomuricin.

**Table 1** AntiSMASH analysis of the secondary metabolite biosynthetic gene clusters of *Nonomuraea* sp. ATCC 55076

Cluster	Location	Structural type	Predicted product	Similarity to characterized biosynthetic gene clusters
1	BKM31_280108-302390	Terpene	Geosmin	Geosmin gene cluster (100%)
2	BKM31_329031-342275	Siderophore		Unknown
3	BKM31_692756-738554	Type I PKS		Thiotetraamide gene cluster (11%)
4	BKM31_1149280-1160095	Bacteriocin		
5	BKM31_1361626-1374873	Siderophore		
6	BKM31_1780967-1852209	NRPS-type III PKS	Kistamicin	A40926 gene cluster (43%)
7	BKM31_2151947-2205643	NRPS		Spinosad gene cluster (8%)
8	BKM31_2596957-2638933	Type III PKS	Alkyl-resorcinol	Alkylresorcinol gene cluster (66%)
9	BKM31_2891146-2912186	Terpene		
10	BKM31_3470395-3514790	Terpene-lantipeptide		Catenulipeptin gene cluster (60%)
11	BKM31_3542307-3586182	Other		
12	BKM31_4190659-4213196	Lasso peptide		
13	BKM31_4679144-4706144	Lantipeptide		
14	BKM31_4941385-4961402	Bacteriocin-proteusin		Daptomycin gene cluster (3%)
15	BKM31_5249766-5270908	Terpene	2-Methyl-isoborneol	2-Methylisoborneol gene cluster (100%)
16	BKM31_5273165-5342461	NRPS	Coelichelin	Coelichelin gene cluster (63%)
17	BKM31_5358340-5379605	Lantipeptide		Rishirilide B gene cluster (7%)
18	BKM31_5380350-5422832	Lasso peptide	Indigoidine	Indigoidine gene cluster (80%)
19	BKM31_5421197-5467325	Type I PKS		Tiacumicin B gene cluster (9%)
20	BKM31_5861156-5883651	Lasso peptide		
21	BKM31_6026507-6038816	Bacteriocin		BE-14106 gene cluster (7%)
22	BKM31_6364194-6386746	Lasso peptide		
23	BKM31_7031092-7072453	Other		
24	BKM31_7183678-7226695	NRPS		
25	BKM31_7211748-7316683	Phenazine	1,6-Dihydroxy-phenazine	Marinophenazines gene cluster (34%)
26	BKM31_7681311-7727480	Type I PKS		Maklamicin gene cluster (6%)
27	BKM31_7918324-7969091	Type II PKS	Xantholipin	Xantholipin gene cluster (42%)
28	BKM31_8119872-8140816	Terpene		
29	BKM31_8820493-8889698	NRPS		Pyridomycin gene cluster (7%)
30	BKM31_9392432-9413598	Terpene		Chlortetracycline gene cluster (5%)
31	BKM31_10970078-10991184	Terpene		
32	BKM31_12946245-13047416	NRPS-aryl-polyene		WS9326 gene cluster (25%)


## 2.4 The kistamicin biosynthetic gene cluster

The kistamicin gene cluster was among those that could be assigned bioinformatically because of its homology to known GPA clusters. A comparison of the complestatin and kistamicin gene clusters is shown (Fig. 4A and Table S5‡). Like complestatin, the *kis* cluster contains four large non-ribosomal peptide synthetases (NRPSs, KisI–KisL). The predicted A-domain specificities are consistent with the amino acid sequence of kistamicin. An X-domain can also be found at the C-terminal end of the ultimate NRPS (KisL), which is likely important for orchestrating the aryl coupling reactions.<sup>18</sup> Interestingly, the *kis* cluster only encodes two P450 enzymes (KisN and KisO), suggesting that one of these catalyzes formation of two crosslinks, possibly the two biaryl ether linkages, leaving the second P450 enzyme for the phenol–indole modification. Alternatively, another P450 enzyme could be encoded elsewhere in the genome; however, a search of the remainder of the ATCC 55076 genome did not reveal a P450 enzyme with sufficiently homology. Accordingly, *kis* is the first GPA cluster in which a bifunctional P450 enzyme is implicated. In all other GPA clusters, a distinct P450 enzyme has been proposed for each aromatic crosslinking reaction.

In addition to the NRPS and P450 enzymes, the genes required for synthesis of Hpg (*kisA*, *kisP*, *kisW*, *kisX*) and Dpg

(*kisQ*–*kisT*) are also contained in the *kis* cluster (Fig. 4A).<sup>10</sup> An FAD-dependent chlorinase (KisU), probably responsible for generating the 3-chloro-4-hydroxy-phenylglycine at the 5th residue of the peptide chain, can also be identified. The sequence of *kis* allows us to propose a biosynthetic pathway for kistamicin, which will guide future studies (Fig. 4B). As with vancomycin and complestatin, we propose production of the 7mer peptide as a thioester-conjugate in a typical NRPS assembly line fashion. The 7mer contains six D-amino acids and one L-amino acid (6th L-Tyr residue). Five epimerization domains can be seen in the four NRPS enzymes suggesting that one perhaps catalyzes two epimerization reactions. In our proposed pathway, the timing of chlorination is based on the recent results by Park *et al.*,<sup>39</sup> in which the complestatin gene cluster was heterologously expressed in *S. lividans*. In this case, chlorination was observed to precede the cyclization reactions, though the timing of chlorination with respect to synthesis of the 7mer peptide remains to be determined. Upon formation of the chlorinated 7mer peptide, we propose that one P450 enzyme catalyzes both aryl ether cyclization reactions, while the second completes kistamicin synthesis by installing the phenol–indole crosslink, again in accordance with recent results with complestatin. The lack of a resistance operon in the *kis* cluster is consistent with a natural function for kistamicin that excludes antibacterial activity or with immunity imparted by other aspects of this strain's physiology.






**Fig. 4** Gene cluster and biosynthetic model for kistamicin. (A) Comparison of the complestatin and kistamicin biosynthetic gene clusters. Genes are colour-coded as indicated (Table S5‡). (B) Biosynthetic model for kistamicin. Four NRPS enzymes, *KisI*–*KisL*, give rise to a peptidyl-carrier protein (PCP)-bound 7mer. Chlorination of the fifth residue, followed by three aromatic cross-coupling reactions, catalyzed by *KisN* and *KisO*, and TE-catalyzed cleavage from the terminal PCP yields kistamicin A.

## 2.5 Expression and purification of OxyA<sub>kis</sub> and OxyB<sub>kis</sub>

As mentioned above, aromatic cross-coupling P450 enzymes are one of the hallmarks of GPA biosynthetic gene clusters. To further characterize this aspect of the *kis* cluster, we cloned and successfully expressed both P450 enzymes (*KisN* and *KisO*) with an N-terminal His<sub>6</sub>-tag in *E. coli* (Table S6‡). Subsequent isolation *via* immobilized metal affinity chromatography followed by thrombin-mediated cleavage of the His<sub>6</sub>-tag yielded purified enzyme (Fig. 5A). UV-vis analysis of both as-purified enzymes showed that they contain the expected heme Soret bands with  $\lambda_{\text{max}}$  of 360 and 415 nm, as well as the so-called Q-bands at 535 and 565 nm, indicative of a typical low-spin Fe<sup>III</sup>-heme (Fig. 5B and S8‡). The UV-vis spectrum revealed substoichiometric levels of heme, with approx. 40–60% of the protein purified in the apo-form. *In vitro* reconstitution with the cofactor led to stoichiometric heme content within both proteins. The P450 enzymes in the



**Fig. 5** Purification of KisN (OxyA<sub>kis</sub>) and KisO (OxyB<sub>kis</sub>). (A) SDS-PAGE gel of Ni-NTA-purified OxyA (exp. 43 kDa) and OxyB (exp. 47 kDa). (B) UV-vis spectrum of purified OxyA<sub>kis</sub> exhibiting spectral properties typical for low-spin Fe<sup>III</sup>-heme. A similar spectrum was obtained for OxyB<sub>kis</sub> (see Fig. S8‡).

kistamicin biosynthetic pathway bind heme and can be purified in high yields setting the stage for future studies with the synthetic substrate. Enzymatic activity of only a small number of GPA P450 enzymes has been reconstituted *in vitro*.<sup>16–20</sup> These assays are complicated by the laborious procedures needed to prepare the substrate, a complex 7mer peptide that is PCP-tethered *via* a pendant phosphopantetheine. Nonetheless, the identification of the *kis* gene cluster and its P450 enzymes provides additional opportunities to examine the fascinating aromatic cross-coupling enzymes.

### 3. Conclusions

We have determined the first complete genome sequence of a *Nonomuraea* species and the sequence of the kistamicin biosynthetic gene cluster. In addition to their remarkable bioactivities, GPAs also boast complex structures that have inspired synthetic and biosynthetic chemists alike. Heroic efforts have led to the total synthesis of a number of GPAs but their biosyntheses, especially installation of the unusual bis-phenol and phenol-indole crosslinks, remain puzzling.<sup>40–42</sup> Our findings will allow future examination of these facets of kistamicin biosynthesis, especially the putative bifunctional P450 enzyme, which may catalyze two crosslinking reactions. Purification of both P450 enzymes reported herein is a first step toward that goal.

We also report that *Nonomuraea* sp. ATCC 55076 contains the largest actinobacterial genome sequenced to date. This strain has a great potential for secondary metabolite biosynthesis with a large amount of genome real estate dedicated to this process. The products of five gene clusters can be putatively assigned in this report. Aside from the kistamicin, geosmin, and 2-methylisoborneol clusters, we also identified 1,6-dihydroxyphenazine as well as nomuricin, a new anthracycline-type secondary metabolite. Collectively, our results suggest that ATCC 55076 will serve as a fruitful target for future genome mining efforts in the hopes of discovering new, bioactive natural products.

## 4. Experimental

### 4.1 Strain, media, and general procedures

*Nonomuraea* sp. ATCC 55076 was obtained from the American Type Culture Collection (ATCC). Glucose-fish meal medium (GFM) was used for production of kistamicin and other secondary metabolites as previously reported.<sup>23</sup> Fish meal was obtained from Petco. Oatmeal agar (ISP Medium 3) was used for sporulation and preparation of mycelial stocks. A modified R4 liquid medium was used as pre-cultures, which were used to inoculate GFM medium (see below). The modified R4 medium contains (per liter) 5 g glucose, 0.5 g of yeast extract, 50 mg casamino acids, 1.5 g L-proline, 1.18 g L-valine, 5 g MgCl<sub>2</sub> hexahydrate, 2 g CaCl<sub>2</sub> dihydrate, 0.1 g K<sub>2</sub>SO<sub>4</sub>, 2.8 g TES and 1 mL of trace elements. It was adjusted to pH 7.2 using NaOH.<sup>43</sup> HPLC separations were carried out on an Agilent 1260 Infinity Series analytical or preparative

HPLC system equipped with a photodiode array detector and an automated fraction collector. High-resolution HPLC-MS was performed on an Agilent UHD Accurate Mass Q-tof LC-MS system, equipped with a 1260 Infinity series HPLC, a JetStream ESI source, and the 6540 Q-tof. Samples were typically resolved on an Agilent Poroshell 120 EC-C18 column (3 × 50 mm, 2.7 μm) at 0.4 mL min<sup>-1</sup> using water and MeCN (both containing 0.1% formic acid). NMR spectra were acquired at the Princeton University Department of Chemistry NMR Facilities. Spectra were collected in MeOD-d4 in the triple resonance cryoprobe of a Bruker A8 Avance III HD 800 MHz NMR spectrometer.

### 4.2 Whole genome sequencing

Genomic DNA from *Nonomuraea* sp. ATCC 55076 was extracted from mycelia grown in modified R4 medium using standard protocols previously described.<sup>44</sup> Briefly, the strain was grown in modified R4 medium at 30 °C and 250 rpm for 48 h. Then genomic DNA was isolated using lysozyme and sodium dodecyl sulphate for cell disruption followed by a phenol-chloroform extraction. The genomic DNA was submitted to the UCI Genomics High-Throughput Facility (GHTF) for library preparation and sequencing. A total of 227 454 reads, each consisting of 7850 bp, were derived from 3 SMRT cell. These were *de novo* assembled using HGAP 3.0.<sup>26</sup> Genome annotation was carried out using the RAST<sup>29</sup> server and graphical mapping was performed with the CIRCOS visualization engine.

### 4.3 Production and purification of kistamicin

Kistamicin production was not observed in ISP2, ISP3, ISP4, and R4 media. To obtain kistamicin, ATCC 55076 was pre-cultured on oatmeal agar for 3 days. The collected mycelium and spores were used to inoculate 0.2 L of modified R4 liquid medium. The pre-cultures were incubated at 250 rpm and 30 °C. After 3 days, the mycelium was collected by centrifugation and used to inoculate 6 × 1 L flasks (each containing 200 mL GFM) at a concentration of 1% (w/v). The GFM cultures were grown at 250 rpm and 30 °C for 9 days. Mycelia were isolated by centrifugation, combined, mixed with 30 mL acetone and vortexed for one minute. Subsequently, the acetone extract was filtered off and the process was repeated. The acetone extracts were combined, dried *in vacuo*, and the residue dissolved in MeOH for analysis by NMR (Fig. S1 and S2‡) and HPLC-Qtof-MS ( $[M + H]^+$ calc 1171.3241,  $[M + H]^+$ obs 1171.3256).

### 4.4 Production and purification of 1,6-dihydroxyphenazine (7)

A total of 4 L of *Nonomuraea* sp. ATCC 55076 were grown in GFM medium at 250 rpm and 30 °C for 9 days, as described above. Cells were removed by centrifugation and the supernatant extracted twice with acidified ethyl acetate (supplemented with 0.1% formic acid). The extract was dried over Na<sub>2</sub>SO<sub>4</sub>, then dried completely *in vacuo*. The residue was resuspended in MeOH and resolved on a



preparative Agilent HPLC on a Phenomenex Luna C18 column (5  $\mu\text{m}$ , 21.2  $\times$  250 mm) at a flow rate of 12 mL min $^{-1}$ . The solvent system consisted of water and MeCN, each containing 0.1% formic acid. A gradient from 20% to 100% MeCN over 40 min was used to purify compound 7, which eluted at 65% MeCN. Compound 7 was purified further on an Agilent Eclipse C8 column (5  $\mu\text{m}$ , 4.6  $\times$  150 mm), a Supelco C18-PEG column (4  $\mu\text{m}$ , 4.6  $\times$  250 mm), and finally a Phenomenex Kinetex Phenyl-hexyl column (5  $\mu\text{m}$ , 4.6  $\times$  100 mm). Elution on each of these columns was performed isocratically at 40% MeCN at 1 mL min $^{-1}$  by monitoring the signal at 280 nm. Pure 7 was characterized by NMR (Fig. S3 and Table S2 $\ddagger$ ) and HR-MS, which gave  $[\text{M} + \text{H}]_{\text{obs}}^+$  213.0654 ( $[\text{M} + \text{H}]_{\text{calc}}^+$  213.0664).

#### 4.5 Production and purification of nomuricin (10)

A total of 4 L of *Nonomuraea* sp. ATCC 55076 were grown in GFM medium at 250 rpm and 30 °C for 9 days, as described above. Cells were removed by centrifugation and the supernatant extracted twice with acidified ethyl acetate (0.1% formic acid). After drying over Na<sub>2</sub>SO<sub>4</sub>, the extract was evaporated *in vacuo*, and the resulting residue resuspended in acetone. Purification of **10** was performed on an Agilent preparative HPLC using a Phenomenex Luna C18 column (5  $\mu\text{m}$ , 21.2  $\times$  250 mm) operating at 12 mL min $^{-1}$ . A gradient from 20% to 100% MeCN over 40 min was used to purify compound **10**, which eluted at 75% MeCN. Compound **10** was purified further on a Phenomenex Phenyl-hexyl column (5  $\mu\text{m}$ , 4.6  $\times$  100 mm), a Supelco C18-PEG column (4  $\mu\text{m}$ , 4.6  $\times$  250 mm), and finally an Agilent Eclipse C8 column (5  $\mu\text{m}$ , 4.6  $\times$  150 mm). Elution on each of these columns was performed isocratically at 45% MeCN at 1 mL min $^{-1}$ . Pure **10** was characterized by UV-vis spectroscopy, NMR (Fig. S4–S6 and Table S3 and S4 $\ddagger$ ) and HR-MS, which gave  $[\text{M} + \text{H}]_{\text{obs}}^+$  463.1035 ( $[\text{M} + \text{H}]_{\text{calc}}^+$  463.1029).

#### 4.6 Cloning, expression, and purification of OxyA<sub>kis</sub> and OxyB<sub>kis</sub>

The *oxyA* and *oxyB* genes from the kistamicin gene cluster in *Nonomuraea* sp. ATCC 55076 were amplified by PCR using kisN-F/kisN-R and kisO-F/kis-O-R primer sets (see Table S6 $\ddagger$ ) and cloned separately into the NdeI and HindIII restriction sites of a pET-28b expression vector, which contains an N-terminal His-tag. The resulting plasmids were transformed into *E. coli* KRX cells for expression of OxyA and OxyB.

*E. coli* KRX cells containing pET-28b<sub>-</sub>OxyA or pET-28b<sub>-</sub>OxyB were cultured in TB media at 37 °C, shaking at 200 rpm until the cultures reached an OD<sub>600nm</sub> between 0.4 and 0.6. Cultures were then induced for 24 hours at 18 °C in the presence of 0.2 mM IPTG and 0.5 mM  $\delta$ -aminolevulinic acid. Following induction, cells were harvested by centrifugation at 8000 g for 20 minutes and then resuspended in 2 mL lysis buffer (50 mM Tris, pH 7.8, 50 mM NaCl, 10 mM imidazole, 5% glycerol, 1 mM  $\beta$ -mercaptoethanol, 1 mg mL $^{-1}$  lysozyme, 1  $\mu\text{L}$  mL $^{-1}$  protease cocktail) per gram of cell pellet. Following

a 1 hour incubation time, the cells were lysed by sonication, and the lysate cleared of cell debris by centrifugation at 32 000g for 1 hour.

OxyA and OxyB were purified from the soluble fractions of respective lysates by Ni-NTA chromatography. Upon loading, elution was carried out with lysis buffer + 100 mM imidazole. The proteins were then desalted on a Sephadex G-25 column. Both OxyA and OxyB exhibited incomplete heme loading following purification as inferred from the UV-visible spectrum (A408:A280 ratios of 1:1 for OxyA and 1:2 for OxyB). Both enzymes were incubated with 10-fold excess hemin on ice for 1 hour. Following reconstitution, excess hemin was removed and the buffer exchanged by Sephadex G-25 chromatography (for 50 mM HEPES, pH 6.8, 50 mM KCl). UV-visible spectra of the reconstituted OxyA and OxyB showed A408:A280 ratios of approximately 2:1 for both enzymes, indicative of complete heme loading.

## Acknowledgements

We thank Dr. Fei Xu for assistance with nomuricin bioactivity assays, as well as the Pew Biomedical Scholars Program and the Princeton Environmental Institute Innovative Research Award for generous support of this work. C. F. and K. R. S. were supported by a Edward C. Taylor 3rd year Fellowship and an Eli Lily-Edward C. Taylor Fellowship in Chemistry, respectively.

## References

1. D. P. Levine, *Clin. Infect. Dis.*, 2006, **42**, 55.
2. K. C. Nicolaou, C. N. Boddy, S. Bräse and N. Winssinger, *Angew. Chem., Int. Ed.*, 1999, **38**, 2096.
3. D. Kahne, C. Leimkuhler, W. Lu and C. Walsh, *Chem. Rev.*, 2000, **105**, 425.
4. J. Pootoolal, J. Neu and G. D. Wright, *Annu. Rev. Pharmacol. Toxicol.*, 2002, **42**, 381.
5. M. H. McCormick, J. M. McGuire, G. E. Pittenger, R. C. Pittenger and W. M. Stark, *Antibiot. Annu.*, 1955, **3**, 606.
6. J. M. McGuire, R. N. Wolfe and D. W. Ziegler, *Antibiot. Annu.*, 1955, **3**, 612.
7. M. R. Bardone, M. Paternoster and C. Coronelli, *J. Antibiot.*, 1978, **31**, 170.
8. T. D. H. Bugg, G. D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin and C. T. Walsh, *Biochemistry*, 1991, **30**, 10408.
9. T. D. H. Bugg, S. Dutka-Malen, P. Arthur, P. Courvalin and C. T. Walsh, *Biochemistry*, 1991, **30**, 2017.
10. B. K. Hubbard and C. T. Walsh, *Angew. Chem., Int. Ed.*, 2003, **42**, 730.
11. G. Yim, M. N. Thaker, K. Koteva and G. Wright, *J. Antibiot.*, 2014, **67**, 31.
12. D. Bischoff, B. Bister, M. Bertazzo, V. Pfeifer, E. Stegmann, G. J. Nicholson, S. Keller, S. Pelzer, W. Wohlleben and R. D. Süssmuth, *ChemBioChem*, 2005, **6**, 267.



Open Access Article. Published on 30 January 2017. Downloaded on 2/22/2026 4:11:22 AM.  
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

13 D. Bischoff, S. Pelzer, B. Bister, G. J. Nicholson, S. Stockert, M. Schirle, W. Wohlleben, G. Jung and R. D. Süssmuth, *Angew. Chem., Int. Ed.*, 2001, **40**, 4688.

14 D. Bischoff, S. Pelzer, A. Höltzel, G. J. Nicholson, S. Stockert, W. Wohlleben, G. Jung and R. D. Süssmuth, *Angew. Chem., Int. Ed.*, 2001, **40**, 1693.

15 R. D. Süssmuth, S. Pelzer, G. Nicholson, T. Walk, W. Wohlleben and G. Jung, *Angew. Chem., Int. Ed.*, 1999, **38**, 1976.

16 K. Zerbe, K. Woithe, D. B. Li, F. Vitali, L. Bigler and J. A. Robinson, *Angew. Chem., Int. Ed.*, 2004, **43**, 6709.

17 K. Woithe, N. Geib, K. Zerbe, D. B. Li, M. Heck, S. Fournier-Rousset, O. Meyer, F. Vitali, N. Matoba, K. Abou-Hadeed and J. A. Robinson, *J. Am. Chem. Soc.*, 2007, **129**, 6887.

18 K. Haslinger, M. Peschke, C. Brieke, E. Maximowitsch and M. J. Cryle, *Nature*, 2015, **521**, 105.

19 K. Haslinger, E. Maximowitsch, C. Brieke, A. Koch and M. J. Cryle, *ChemBioChem*, 2014, **15**, 2719.

20 M. Peschke, C. Brieke and M. J. Cryle, *Sci. Rep.*, 2016, **6**, 35584.

21 H. T. Chiu, B. K. Hubbard, A. N. Shah, J. Eide, R. A. Fredenburg, C. T. Walsh and C. Khosla, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 8548.

22 T. Fujioka, K. Furuhata, I. Kaneko, S. Takahashi and H. Seto, *J. Antibiot.*, 1988, **41**, 606.

23 N. Naruse, M. Oka, M. Konishi and T. Oki, *J. Antibiot.*, 1993, **46**, 1812.

24 H. B. Bode, B. Bethe, R. Höfs and A. Zeeck, *ChemBioChem*, 2002, **3**, 619.

25 J. Eid, *et al.*, *Science*, 2009, **323**, 133.

26 C. S. Chin, D. H. Alexander, P. Marks, A. A. Klammer, J. Drake, C. Heiner, A. Clum, A. Copeland, J. Huddleston, E. E. Eichler, S. W. Turner and J. Korlach, *Nat. Methods*, 2013, **10**, 563.

27 R. Sungthong and N. Nakaew, *J. Basic Microbiol.*, 2015, **55**, 554.

28 X. J. Wang, *et al.*, *J. Bacteriol.*, 2010, **192**, 4526.

29 R. K. Aziz, *et al.*, *BMC Genomics*, 2008, **9**, 75.

30 T. Weber, *et al.*, *Nucleic Acids Res.*, 2015, **43**, W237.

31 G. L. Challis and D. A. Hopwood, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 14555.

32 M. H. Medema, *et al.*, *Nat. Chem. Biol.*, 2015, **11**, 625.

33 D. Yu, F. Xu, J. Valiente, S. Wang and J. Zhan, *J. Ind. Microbiol. Biotechnol.*, 2013, **40**, 159.

34 S. Lautru, R. J. Deeth, L. M. Bailey and G. L. Challis, *Nat. Chem. Biol.*, 2005, **1**, 265.

35 H. Akabori and M. Nakamura, *J. Antibiot.*, 1959, **12**, 17.

36 T. Oki, M. Konishi, K. Tomatsu, K. Tomita, K. Saitoh, M. Tsunakawa, M. Nishio, T. Miyaki and H. Kawaguchi, *J. Antibiot.*, 1988, **41**, 1701.

37 Y. Sawada, T. Tsuno, T. Ueki, H. Yamamoto, Y. Fukagawa and T. Oki, *J. Antibiot.*, 1993, **46**, 507.

38 W. Zhang, L. Wang, L. Kong, T. Wang, Y. Chu, Z. Deng and D. You, *Chem. Biol.*, 2012, **19**, 422.

39 O. K. Park, H. Y. Choi, G. W. Kim and W. G. Kim, *ChemBioChem*, 2016, **17**, 1725.

40 D. A. Evans, M. R. Wood, B. W. Trotter, T. I. Richardson, J. C. Barrow and J. L. Katz, *Angew. Chem., Int. Ed.*, 1998, **37**, 2700.

41 K. C. Nicolaou, H. J. Mitchell, N. F. Jain, N. Winssinger, R. Hughes and T. Bando, *Angew. Chem., Int. Ed.*, 1999, **38**, 240.

42 D. L. Boger, S. Miyazaki, S. H. Kim, J. H. Wu, S. L. Castle, O. Loiseleur and Q. Jin, *J. Am. Chem. Soc.*, 1999, **121**, 10004.

43 J. Shima, A. Hesketh, S. Okamoto, S. Kawamoto and K. Ochi, *J. Bacteriol.*, 1996, **178**, 7276.

44 T. Kieser, M. J. Bibb, M. J. Buttner, K. F. Chater and D. A. Hopwood, *Practical Streptomyces Genetics*, John Innes Foundation, Norwich (UK), 2000, pp. 4161–4171.

